This content is only available within our institutional offering.

22 Feb 2024
Hikma Pharmaceuticals (HIK LN, 2,340p, Buy) (Results Review) - FY23: small beat (underlying), and better-than-expected outlook

Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
Hikma Pharmaceuticals (HIK LN, 2,340p, Buy) (Results Review) - FY23: small beat (underlying), and better-than-expected outlook
Hikma Pharmaceuticals Plc (HIK:LON) | 1,826 -237.4 (-0.7%) | Mkt Cap: 4,052m
- Published:
22 Feb 2024 -
Author:
Miles Dixon -
Pages:
8 -